Ask AI

Why B7-H3 Is a Clinically Relevant Target in ES-SCLC

Video
This activity is available for 0.50 CME/CE credit(s).

Released: October 27, 2026

Expiration: April 26, 2027

See Activity Collection

The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Watch this video to learn more about the importance of lung cancer screening, why ES-SCLC remains a setting in need of novel treatment options and strategies, an overview of the currently approved treatments for patients with this disease, the evolving targeted therapy landscape, biology and rationale for investigating therapies targeting B7-H3, overview of clinical evidence with the use of investigational B7-H3–directed antibody–drug conjugates such as ifinatamab deruxtecan, risvutatug rezetecan, tambotatug pelitecan and elfetabart drozuntecan, and key ongoing phase III trials of B7-H3–directed therapies.

Overview of B7 H3 in ES-SCLC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with lung cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following most accurately reflects the rationale for the use of ADCs targeting B7-H3 in SCLC?

How confident are you in your answer?